Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Forge Announces Visible Gold & Continued Porphyry Mineralization at Alotta Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Revelation Biosciences Inc REVB

Healthcare Biotechnology
Revelation Biosciences, Inc. is a clinical-stage life sciences company engaged in the development of innate immune system therapeutics and diagnostics. Its therapeutic candidates are based on its Gemini formulation of active ingredient phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA) that is known to stimulate Toll-like receptor 4 (TLR-4). Its... see more

Recent & Breaking News (NDAQ:REVB)

Revelation Biosciences, Inc. Announces Pricing of $4 Million Public Offering

Business Wire May 29, 2025

Revelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of Directors

Business Wire May 23, 2025

Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025

Business Wire May 8, 2025

Revelation Biosciences to Develop Gemini for Infection in Severe Burn Patients

Business Wire April 29, 2025

Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells

Business Wire March 17, 2025

Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference

Business Wire March 13, 2025

Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024

Business Wire March 6, 2025

Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients

Business Wire February 26, 2025

Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval

Business Wire February 24, 2025

Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025

Business Wire January 24, 2025

Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients

Business Wire January 21, 2025

Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025

Business Wire January 13, 2025

Nasdaq Grants Revelation Biosciences Inc. Continued Listing

Business Wire January 6, 2025

Revelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross Proceeds

Business Wire December 3, 2024

Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND

Business Wire December 2, 2024

Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply

Business Wire November 12, 2024

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024

Business Wire November 8, 2024

Revelation Biosciences' Gemini Induces Dose Dependent Significant Increases in IL-10

Business Wire September 24, 2024

Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds

Business Wire August 21, 2024

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024

Business Wire August 9, 2024